Table 4. Imaging results and circulating tumour cell numbers.
| Total | No Prior Chemotherapy | Prior Chemotherapy | |
|---|---|---|---|
| Soft tissue | 59 | 25 | 34 |
| Partial response | 13 (22%) | 9 (36%) | 4 (12%) |
| Stable disease | 29 (49%) | 11 (44%) | 18 (53%) |
| Bone scan (week 12) | 109 | 41 | 68 |
| Stable disease | 61 (56%) | 26 (63%) | 35 (51%) |
| FDG PET (week 12)a | 22 | 11 | 11 |
| >25% decline from baseline | 10 (45%) | 6 (55%) | 4 (45%) |
| <25% decline | 12 (55%0 | 7 (64%) | 5 (45%) |
| Circulating tumour cell numberb | 128 | 60 | 68 |
| <5 at baseline | 77 | 44 | 33 |
| < 5 on treatment | 70 (91%) | 40 (91%) | 30 (91%) |
| ≥ 5 on treatment | 7 (9%) | 4 (9%) | 3 (9%) |
| ≥ 5 at baseline | 51 | 16 | 35 |
| < 5 on treatment | 25 (49%) | 12 (75%) | 13 (37%) |
| ≥ 5 on treatment | 26 (51%) | 4 (25%) | 22 (63%) |
a
All 22 patients had at least one FDG-avid lesion that could be used as an index lesion, and the breakdown in terms of patients was 5 index lesions: 16; 4 index lesions: 3; 2 index lesions: 1; 1 index lesion: 1. The range of SUVmax average varied from 2.72 to 16.6 in the 22 patients, and the median SUVmax average was 5.025.
b
<5 CTCs per 7.5 ml is considered favourable; ≥5 is considered unfavourable.